StreetInsider.com News Articles

Form SCHEDULE 13G Ultragenyx Pharmaceutica Filed by: Madison Avenue Partners, LP

Tue, 20 Oct 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20261020/27211391.html

Form 4 Ultragenyx Pharmaceutica For: Oct 15 Filed by: Horn Howard

Mon, 19 Oct 2026 13:49:00 -0400

si-local-file:///var/storage/secattach/20261019/27203185.html

Form 8-K Ultragenyx Pharmaceutica For: Oct 19

Mon, 19 Oct 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20261019/27201550.html

UBS Starts Ultragenyx Pharma (RARE) at Neutral

Wed, 14 Oct 2026 16:45:29 -0400

UBS initiates coverage on Ultragenyx Pharma (NASDAQ: RARE) with a Neutral rating and a price target of $16.00.

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $14.92 yesterday.

Form 8-K Ultragenyx Pharmaceutica For: Oct 08

Wed, 14 Oct 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20261014/27184678.html

Ultragenyx agrees to sell rare pediatric disease PRV for $203M

Wed, 14 Oct 2026 08:30:13 -0400

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million, according to a company statement.

The PRV was received upon U.S. Food and Drug Administration approval of FAYUVI (rebisufligene etisparvovec-hopf), a treatment for mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A). The company described FAYUVI as the first FDA-approved treatment for that condition.

The transaction represents Ultragenyx's second PRV sale within one week, following a previously announced sale tied to its GENGLYCOS product.

Howard Horn, chief financial officer and executive vice president of corporate strategy, said: "The sale

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

Wed, 14 Oct 2026 08:30:00 -0400

Agreement marks the Company’s second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction

NOVATO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, the first-ever FDA-approved treatment for mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A).

“The sale of this PRV delivers meaningful non-dilutive funding that strengthens

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

Wed, 14 Oct 2026 08:30:00 -0400

Agreement marks the Company’s second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction

“The sale of this PRV delivers meaningful non-dilutive funding that strengthens

H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Thu, 08 Oct 2026 07:00:21 -0400

H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $25.00 price target on Ultragenyx Pharma (NASDAQ: RARE).

The analyst commented: "Yesterday, Ultragenyx announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210M. Ultragenyx received the PRV upon FDA approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, the first treatment designed to address the underlying cause of glycogen storage disease type Ia (GSDIa). The closing of the PRV transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.

Form 8-K Ultragenyx Pharmaceutica For: Oct 06

Wed, 07 Oct 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20261007/27158899.html

Ultragenyx to sell rare pediatric disease voucher for $210 million

Wed, 07 Oct 2026 08:30:12 -0400

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million, according to a company press release.

Ultragenyx received the PRV following U.S. Food and Drug Administration approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), a treatment for glycogen storage disease type Ia (GSDIa).

Howard Horn, chief financial officer and executive vice president of corporate strategy, said the proceeds represent "non-dilutive capital" that will support the company's pipeline and its "path to profitability."

Closing of the transaction is subject to customary conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Wed, 07 Oct 2026 08:30:00 -0400

NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, the first treatment designed to address the underlying cause of glycogen storage disease type Ia (GSDIa).

“Monetizing this PRV provides significant non-dilutive capital to advance our efforts to bring forward first-ever therapies for rare and ultra-rare diseases, and supports our path

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Wed, 07 Oct 2026 08:30:00 -0400

“Monetizing this PRV provides significant non-dilutive capital to advance our efforts to bring forward first-ever therapies for rare and ultra-rare diseases, and supports our path

H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Fri, 25 Sep 2026 06:47:05 -0400

H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $25.00 price target on Ultragenyx Pharma (NASDAQ: RARE).

The analyst commented: "Ultragenyx recently reported that the FDA had granted standard full approval of FAYUVI (rebisufligene etisparvovec-hopf), also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A). FAYUVI is the first-ever FDA-approved treatment for Sanfilippo syndrome Type A, and the second gene therapy approval for Ultragenyx. Sanfilippo syndrome Type A is an ultra-rare, fatal lysosomal storage disease that primarily affects the brain and is marked by rapid, progressive neurodegeneration beginning in early

Ultragenyx Pharma (RARE) PT Raised to $20 at Morgan Stanley

Mon, 21 Sep 2026 08:39:31 -0400

Morgan Stanley analyst Maxwell Skor raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $20.00 (from $18.00) while maintaining a Equalweight rating.

Ultragenyx Pharma (RARE) PT Raised to $35 at Barclays

Mon, 21 Sep 2026 05:07:41 -0400

Barclays analyst Eliana Merle raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $35.00 (from $32.00) while maintaining a Overweight rating.

Ultragenyx Pharma (RARE) PT Raised to $20 at Morgan Stanley

Fri, 18 Sep 2026 08:15:01 -0400

Morgan Stanley analyst Maxwell Skor raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $20.00 (from $18.00) while maintaining a Equalweight rating.

Ultragenyx Pharma (RARE) PT Raised to $39 at Cantor Fitzgerald on FAYUVI Approval

Fri, 18 Sep 2026 07:01:33 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $39.00 (from $33.00) while maintaining a Overweight rating.

The analyst commented, "Today, 9/17, Ultragenyx announced the approval of FAYUVI (UX111, AAV9-based gene therapy) for Sanfilippo syndrome type A (MPS IIIA). Congrats to the Ultragenyx and Abeona (OW) teams on this approval for a patient group that has long awaited an effective treatment option. As a reminder, MPS IIIA is a rare fatal genetic neurodegenerative condition caused by SGSH mutations, leading to the toxic buildup of heparan sulfate. We estimate it impacts >3,000 patients worldwide. With this

Ultragenyx Pharma (RARE) PT Raised to $39 at Cantor Fitzgerald on FAYUVI Approval

Fri, 18 Sep 2026 07:01:33 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $39.00 (from $33.00) while maintaining a Overweight rating.

Ultragenyx Pharma (RARE) PT Raised to $39 at Canaccord

Fri, 18 Sep 2026 06:43:41 -0400

Canaccord analyst Whitney Ijem raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $39.00 (from $37.00) while maintaining a Buy rating.

The analyst commented:"As expected, and slightly ahead of its 9/19/26 PDUFA, Ultragenyx’s AAV9 gene therapy UX111 was approved by the FDA as FAYUVI for pediatric patients with MPS IIIA/Sanfilippo syndrome Type A with preserved neurodevelopmental function. FAYUVI is the first FDA-approved treatment for MPS IIIA and the company’s second gene therapy approval. The drug will be priced at $3.95M gross (ahead of our conservative $2M estimate) and is expected to ship to QTCs within 30-60 days. The co also

Ultragenyx Pharma (RARE) PT Raised to $39 at Canaccord

Fri, 18 Sep 2026 06:43:41 -0400

Canaccord analyst Whitney Ijem raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $39.00 (from $37.00) while maintaining a Buy rating.

Citi raises Ultragenyx Pharma price target to $32

Fri, 18 Sep 2026 05:17:20 -0400

Citi analyst Yigal Nochomovitz raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $32.00 from $31.00, while maintaining a Buy rating.

The revision follows the approval of FAYUVI, with the analyst noting the FDA granted full approval rather than accelerated approval, which Nochomovitz described as "a strong regulatory outcome reflecting the agency's confidence in the dataset."

The approved label covers the full pediatric age range, with management estimating the average initial candidate could be approximately five years old, though some functional patients may remain eligible through age 10. The label's "preserved neurodevelopmental function" language does not require a formal testing threshold,

Form 8-K Ultragenyx Pharmaceutica For: Sep 17

Thu, 17 Sep 2026 15:56:00 -0400

si-local-file:///var/storage/secattach/20260917/27075648.html

FDA approves Ultragenyx gene therapy for rare childhood disease

Thu, 17 Sep 2026 15:48:58 -0400

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that the U.S. Food and Drug Administration granted standard full approval of FAYUVI (rebisufligene etisparvovec-hopf) for the treatment of pediatric patients with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome Type A.

According to the company's press release, FAYUVI is the first FDA-approved treatment for Sanfilippo syndrome Type A, a progressive neurodegenerative disease estimated to affect approximately 3,000 to 5,000 patients in commercially accessible geographies, with a median life expectancy of 15 years. The disease is caused by a deficiency of the sulfamidase enzyme, resulting in the accumulation of heparan sulfate in cells and progressive

FDA approves Ultragenyx gene therapy for rare childhood disease

Thu, 17 Sep 2026 15:48:58 -0400